Compare GCO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | ALT |
|---|---|---|
| Founded | 1924 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.0M | 421.5M |
| IPO Year | 1994 | 2005 |
| Metric | GCO | ALT |
|---|---|---|
| Price | $38.42 | $3.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $33.00 | $17.67 |
| AVG Volume (30 Days) | 137.7K | ★ 4.0M |
| Earning Date | 06-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,606,898,000.00 | $41,000.00 |
| Revenue This Year | $0.78 | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.71 | ★ 105.00 |
| 52 Week Low | $21.93 | $2.56 |
| 52 Week High | $43.60 | $6.44 |
| Indicator | GCO | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 53.13 |
| Support Level | $31.11 | $2.65 |
| Resistance Level | $38.72 | $3.09 |
| Average True Range (ATR) | 1.48 | 0.17 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 67.48 | 44.64 |
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.